Liverpool School of Tropical Medicine is using Delta eSourcing to run this tender exercise
| Notice Summary |
|---|
| Title: | GB-Liverpool: LW072 Tender for Albendazole and Placebo for a Phase 2 Clinical Trial |
| Notice type: | Competitive Contract Notice |
| Authority: | Liverpool School of Tropical Medicine |
| Nature of contract: | Not applicable |
| Procedure: | Not applicable |
| Short Description: | STM, together with colleagues at the Department of Chemistry of the University of Liverpool (UoL), The University Hospital Bonn, the University of Buea in Cameroon and the Japanese pharmaceutical company Eisai, are developing a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis. These are both debilitating infections that affect more than 150 million people globally. The drug candidate, AWZ1066S is funded to enter a Phase II clinical trial in 2023 and the design of the trial requires the supply of Albendazole and an Albendazole placebo for use in the clinical trial. |
| Published: | 11/11/2022 15:30 |
View Full Notice
1. Title: GB-Liverpool: LW072 Tender for Albendazole and Placebo for a Phase 2 Clinical Trial
2. Awarding Authority:
Liverpool School of Tropical Medicine
Pembroke Place, Liverpool, Liverpool, L3 5QA, United Kingdom
Tel. +44 1517053152, Email: tenders@lstmed.ac.uk, URL: http://www.lstmed.ac.uk/
Contact: Procurement, Attn: Liz Wilson
3. Contract Type: Services
Sub Type: Research and development services.
4. Description: Research and experimental development services. STM, together with colleagues at the Department of Chemistry of the University of Liverpool (UoL), The University Hospital Bonn, the University of Buea in Cameroon and the Japanese pharmaceutical company Eisai, are developing a new drug to target the neglected tropical diseases lymphatic filariasis (LF) and onchocerciasis. These are both debilitating infections that affect more than 150 million people globally. The drug candidate, AWZ1066S is funded to enter a Phase II clinical trial in 2023 and the design of the trial requires the supply of Albendazole and an Albendazole placebo for use in the clinical trial.
5. CPV Codes:
73100000 - Research and experimental development services.
6. NUTS Codes :
UKD72 - Liverpool
7. Main Site or Location of Works, Main Place of Delivery or Main Place of Performance: Liverpool,
8. Reference Attributed by the Awarding Authority: LW072
9. Estimated Value of Requirement: Category I: 50K to 100K
Currency: GBP
10. Deadline for Expression of Interest: 06/12/2022 12:00:00
11. Address to which they must be sent:
Not Provided
12. Other Information:
Other Information: The contracting authority considers that this contract may be suitable for economic operators that are small or medium enterprises (SMEs). However, any selection of tenderers will be based solely on the criteria set out for the procurement.
For more information about this opportunity, please visit the Delta eSourcing portal at:
https://www.delta-esourcing.com/tenders/UK-GB-Liverpool:-LW072-Tender-for-Albendazole-and-Placebo-for-a-Phase-2-Clinical-Trial/8MGNUR2Q3K
To respond to this opportunity, please click here:
https://www.delta-esourcing.com/respond/8MGNUR2Q3K
TKR-20221111-PRO-21422412
Suitable for VCO: Yes
Procedure Type:OPEN
Period of Work Start date: 02/01/2023
Period of Work End date: 31/12/2024
Is this a Framework Agreement?: no